Dr Fiona Mosgrove (GP with special interest in respiratory medicine) is joined by Professor Mona Bafadhel (Director for King's Centre for Lung Health and Chair of Respiratory Medicine at King's College) and Christine Mwasuku (Research Nurse and First Year PhD candidate funded by Asthma+LungUK) to

PCRS believe that it is the responsibility of every healthcare professional to treat tobacco dependency systematically and effectively. PCRS advocate that people wishing to quit using tobacco should be offered the most effective but also the least harmful methods first to support a quit attempt.

PCRS recognises a need for improvement in the timely diagnosis of people living with chronic breathlessness and generally welcomes the NHS England diagnostic pathway support tool. PCRS has some concerns that a diagnostic algorithm can communicate an oversimplification of diagnosis.

In 2023, the Medicines and Healthcare Products Regulatory Agency (MHRA) approved the use of a dual (Inhaled corticosteroid/ Formoterol) combination treatment to be used as a reliever therapy for people aged 12 and over with the therapy choice situated early in the asthma treatment pathway as an a

PCRS advocate a pragmatic approach to the pharmacological management of patients with COPD guided by the predominance of breathlessness and/or exacerbations and the presence or absence of comorbid asthma.

The report explored the link between inequality and lung disease and the primary conclusions were:

A new report is showcasing the impact of a national AHSN Network programme to improve access to FeNO testing for asthma diagnosis. Fractional exhaled Nitric Oxide (FeNO) tests are simple, non-invasive tests to support the diagnosis of asthma.

The PCRS Patient Reference Group (PRG) is a small group of people with respiratory conditions who support PCRS to ensure that we always try to embed the patient perspective in our work and consider the holistic management of patients.

Have you booked your place at this year’s conference yet? Early bird registration is now open for you to secure your place and join us in Telford for the UK’s leading respiratory conference for clinicians working in primary, community, and integrated care.

This pragmatic guide focuses on the ongoing management of adults and children with severe asthma receiving biologic therapy and has been developed by an expert group led by Will Carroll, University Hospital of the North Midlands, Stoke-on-Trent and including Ernie Wong, Imperial College Healthcar

In an ideal world, asthma review appointments will be between 20 to 30 minutes in duration. But we are not living in an ideal world.

The Medicines and Healthcare Products Regulatory Agency (MHRA) has for the first time approved the use of a dual (ICS/beta-agonist) combination treatment to be prescribed as a reliever therapy for people aged 12 and over with the therapy choice situated early in the asthma treatment pathway as an

To consider how and when we use FeNO testing, we need to go to the definition of asthma. Both BTS/SIGN1 and GINA2 define it as a predominantly inflammatory disorder of the airways with airway hyperresponsiveness and variability in symptoms.